The ongoing ORION-13 and ORION-16 trials are designed to evaluate the efficacy and safety of inclisiran versus placebo in adolescents with familial hypercholesterolemia.
RCT (n=162)
Double-blind
Yes
Does inclisiran reduce LDL-C in adolescents with homozygous or heterozygous familial hypercholesterolaemia?
The ORION-13 and ORION-16 trials will evaluate whether inclisiran safely and effectively lowers LDL-C in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
BACKGROUND: Inclisiran is a small interfering RNA molecule that reduces low-density lipoprotein cholesterol (LDL-C) by inhibition of proprotein convertase subtilisin/kexin type 9. This subcutaneous, twice-yearly administered agent has been shown to effectively and safely lower LDL-C in adult patients with established atherosclerotic cardiovascular disease, adults at high risk for atherosclerotic cardiovascular disease, as well as in adults with heterozygous familial hypercholesterolaemia. With the current, limited treatment options available to reach treatment goals in children with severe heterozygous familial hypercholesterolaemia, homozygous familial hypercholesterolaemia, or statin intolerance, inclisiran could be a valuable new therapeutic option. OBJECTIVES: The objective of these ongoing studies is to investigate the efficacy, safety, and tolerability of inclisiran in adolescents diagnosed with homozygous familial hypercholesterolaemia (ORION-13) or heterozygous familial hypercholesterolaemia (ORION-16). STUDY DESIGN: ORION-13 and ORION-16 are both two-part (1-year double-blind inclisiran vs. placebo/1 year open-label inclisiran) multicentre trials including adolescents aged 12 to <18 years diagnosed with familial hypercholesterolaemia. ORION-13 will include ∼12 participants diagnosed with homozygous familial hypercholesterolaemia and ORION-16 will include ∼150 participants diagnosed with heterozygous familial hypercholesteroleamia. The primary endpoint is the percentage change in LDL-C from baseline to Day 330. Secondary efficacy and safety endpoints include changes in other lipid parameters and treatment-emergent adverse events as well as laboratory parameters and vital signs. Exploratory endpoints include individual responsiveness of the participants and change in LDL-C according to the type of underlying causal mutation. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov/. Unique identifier: NCT04659863 (ORION-13) and NCT04652726 (ORION-16).
Reijman et al. (Tue,) conducted a rct in Familial hypercholesterolaemia (n=162). Inclisiran vs. Placebo was evaluated on Percentage change in LDL-C from baseline to Day 330. The ongoing ORION-13 and ORION-16 trials are designed to evaluate the efficacy and safety of inclisiran versus placebo in adolescents with familial hypercholesterolemia.